Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02700841 · ClinicalTrials.gov registry record · Phase 2
Enhancing Anti--Tetanus Vaccine Response After Autologous Stem Cell Transplantation
A Phase 2 study, sponsored by University of Nebraska.
- Terminated
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT02700841 is a Phase 2 study that was terminated before completion, run by University of Nebraska. The registered enrollment target is 8 participants.
The verdict
NCT02700841, a Phase 2 study, was terminated before completion, sponsored by University of Nebraska.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
This pilot randomized Phase II trial (10 subjects per arm) will compare immune reconstitution following transplantation of an autologous mobilized graft product to reconstitution following transplantation of a mobilized graft product followed by an autologous lymphocyte infusion collected prior to G-CSF mobilization. All subjects will receive tetanus vaccines pre and post-transplant. The primary end point will be tetanus vaccine immune responses post-transplant.
Interventions
- DRUG Melphalan
- BIOLOGICAL T Cell-Depleted Hematopoietic Stem Cell Transplantation
- BIOLOGICAL Tetanus Toxoid Vaccine
- PROCEDURE Peripheral Blood Stem Cell Transplantation--CD34 HSCT
- PROCEDURE Peripheral Blood Stem Cell Transplantation--AHSCT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2020-01-09 |
| Est. Completion | 2022-12-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02700841
The ClinicalTrials.gov registry entry for NCT02700841 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Nebraska, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Melphalan is the first listed.
NCT02700841 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02700841 about?
NCT02700841 is a clinical study titled "Enhancing Anti--Tetanus Vaccine Response After Autologous Stem Cell Transplantation". This pilot randomized Phase II trial (10 subjects per arm) will compare immune reconstitution following transplantation of an autologous mobilized graft product to reconstitution following transplantation of a mobilized graft product followed by an autologous lymphocyte infusion collected prior to G...
What is the current status of trial NCT02700841?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2020-01-09. Estimated completion is 2022-12-21.
What interventions are being tested in trial NCT02700841?
The interventions under investigation include: Melphalan (DRUG), T Cell-Depleted Hematopoietic Stem Cell Transplantation (BIOLOGICAL), Tetanus Toxoid Vaccine (BIOLOGICAL), Peripheral Blood Stem Cell Transplantation--CD34 HSCT (PROCEDURE), Peripheral Blood Stem Cell Transplantation--AHSCT (PROCEDURE).
Who is sponsoring clinical trial NCT02700841?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.